Observational studyAmerican journal of respiratory and critical care medicine2018
Validation of a Host Response Assay, SeptiCyte LAB, for Discriminating Sepsis from Systemic Inflammatory Response Syndrome in the ICU.
Observational study in American journal of respiratory and critical care medicine, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. It is linked to 2 registered trials, which are not on this map. Cited by 67 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Molecular Diagnosis and Risk Stratification of Sepsis
VENUS: Validation of Septic Gene ExpressioN Using SeptiCyte®
Who cites it
67 citing papers in PubMed.
- Intensive care infection score outperforms inflammatory biomarkers in detecting infection in critically ill patients.Infection · 2026Article
- Sequential Application of Time-Stratified Demographic, Vital, Clinical-Laboratory, and Microbiology Variables for Accurate and Rapid Identification of Sepsis.Diseases (Basel, Switzerland) · 2026Article
- Early Identification of a Cytokine-Low Immune Phenotype in Suspected Sepsis Using a Point-of-Care Whole-Blood TNF-α Release Assay.Medical sciences (Basel, Switzerland) · 2026Article
- Ruling In and Ruling Out Sepsis Using Likelihood Ratios of a Host Response Assay.Diagnostics (Basel, Switzerland) · 2026Article
- Clinical evaluation of the SeptiScore biomarker for the diagnosis of healthcare-associated infections in critically ill trauma patients: a multicenter derivation and validation cohort study.BMC anesthesiology · 2026Observational
- Diagnostic accuracy of SeptiCyte® RAPID to discriminate sepsis from non-infectious critical illness in patients meeting sepsis criteria according to sepsis-3 definition at ICU admission.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2026Observational
- Host Transcriptomics and Culture-Independent Testing for the Management of Febrile Neutropenia: Data From an Observational Study Conducted in a Bone Marrow Transplant Unit.European journal of haematology · 2026Observational
- Likelihood of Blood Culture Positivity Using SeptiCyte RAPID.Journal of clinical medicine · 2026Article
- Genomic and integrative based progression biomarker discovery in adult sepsis: toward clinical stratification and precision medicine.Annals of intensive care · 2026Review
- From genes to clinical application: a circulating four-gene signature for early diagnosis model of refractoryFrontiers in cellular and infection microbiology · 2026Article
- Early biomarkers for predicting sepsis-induced shock: insights from inflammatory pathways and immune response.Frontiers in pharmacology · 2026Review
- Blood Host-Response mRNA Assays in Adult Acute Care: Diagnostic Performance, Translational Evidence, and the Clinical Implementation Gap.Infection and drug resistance · 2026Review
- Point-of-care LPS-induced TNF-α release testing for early sepsis risk stratification in the emergency department.Frontiers in immunology · 2026Observational
- Hyper-inflammation and immunosuppression: redefining sepsis therapy using modern approaches.Frontiers in pharmacology · 2026Review
- Blood transcriptomic for the diagnosis of nosocomial infections in critically ill patients: an observational proof-of-concept study.Infection · 2025Observational
- Minimalistic transcriptomic signatures permit accurate early prediction of COVID-19 mortality.JCI insight · 2025Article
- Rapid, Amplification-free, RNA-based Uropathogen Detection With LbuCas13a.Open forum infectious diseases · 2025Article
- Evaluating the InSignia IFI27 expression assay for detecting viral respiratory infection compared to a traditional gene normalisation assay.Scientific reports · 2025Article
- SeptAsTERS- SeptiCyte® RAPID as assessment tool for early recognition of sepsis - a prospective observational study.Infection · 2025Observational
- Likelihood of blood culture positivity using SeptiCyte RAPID.medRxiv : the preprint server for health sciences · 2025Article
7 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
- Erratum issued
Authors and funding
42 authors.
Funding
Abstract
rationaleA molecular test to distinguish between sepsis and systemic inflammation of noninfectious etiology could potentially have clinical utility.
objectivesThis study evaluated the diagnostic performance of a molecular host response assay (SeptiCyte LAB) designed to distinguish between sepsis and noninfectious systemic inflammation in critically ill adults.
methodsThe study employed a prospective, observational, noninterventional design and recruited a heterogeneous cohort of adult critical care patients from seven sites in the United States (n = 249). An additional group of 198 patients, recruited in the large MARS (Molecular Diagnosis and Risk Stratification of Sepsis) consortium trial in the Netherlands ( www.clinicaltrials.gov identifier NCT01905033), was also tested and analyzed, making a grand total of 447 patients in our study. The performance of SeptiCyte LAB was compared with retrospective physician diagnosis by a panel of three experts. MEASUREMENTS AND MAIN
resultsIn receiver operating characteristic curve analysis, SeptiCyte LAB had an estimated area under the curve of 0.82-0.89 for discriminating sepsis from noninfectious systemic inflammation. The relative likelihood of sepsis versus noninfectious systemic inflammation was found to increase with increasing test score (range, 0-10). In a forward logistic regression analysis, the diagnostic performance of the assay was improved only marginally when used in combination with other clinical and laboratory variables, including procalcitonin. The performance of the assay was not significantly affected by demographic variables, including age, sex, or race/ethnicity.
conclusionsSeptiCyte LAB appears to be a promising diagnostic tool to complement physician assessment of infection likelihood in critically ill adult patients with systemic inflammation. Clinical trial registered with www.clinicaltrials.gov (NCT01905033 and NCT02127502).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.